Research
Hormonal
Adiponectin levels are inversely correlated with visceral fat mass and insulin resistance, and low levels are associated with increased cardiovascular risk.
Adiponectin is a beneficial hormone that improves insulin sensitivity and protects heart health. Its levels tend to be lower in people with high visceral fat. While you cannot directly 'take' adiponectin, lifestyle changes like exercise and weight loss can help increase your body's natural production of it.
GoodSupportsHIGH confidence
We have recently shown that adiponectin serum concentration negatively correlates with visceral fat mass... low adiponectin serum concentrations are associated with increased risk for cardiovascular disease
Why this rating
Supported by multiple studies cited in the review.
Source
Clinical Relevance of Adipokines
Matthias Blüher · Diabetes & Metabolism Journal · 2012
DOI 10.4093/dmj.2012.36.5.317
narrative_reviewCited 199×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- DPP-4 inhibitors lower hyperglycemia in type 2 diabetes by preventing the degradation of incretin hormones (GLP-1 and GIP), thereby potentiating glucose-dependent insulin secretion.Strong
- Adipokines such as leptin and adiponectin serve as critical biomarkers for visceral fat distribution, insulin sensitivity, and metabolic risk, with altered secretion patterns linking obesity to cardiovascular and metabolic diseases.Good
- Exogenous leptin administration is an effective treatment for genetic leptin deficiency and lipodystrophy, but fails to significantly reduce body weight in common obesity due to central leptin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →